- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05765006
CD19-CART(Relma-cel) for Moderate to Severe Active Systemic Lupus Erythematosus
A Phase I Dose-escalation Study Evaluate the Safety Tolerability Pharmacokinetics(PK) and Pharmacodynamics(PD) of Relma-cel in Subjects With Moderate to Severe Active Systemic Lupus Erythematosus (SLE)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a phase I, open-label, single-arm, multicenter study to asess the safety tolerability pharmacokinetics(PK) and pharmacodynamics(PD) of Relma-cel in moderate or severe active systemic lupus erythematosus (SLE) subjects in China.
There will be 4 dose level (15x106 CAR+ T cells as the back up dose ,25x106 CAR+ T cells as the starting dose 、50x106 CAR+ T cells and 100x106(or 150 x106CAR+ T cells)Dose escalation, to evaluate the safety、 tolerability of Relma-cel in adult subjects of SLE and determine RP2D .
Study Type
Enrollment (Anticipated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: medical JW
- Phone Number: +86 21 50464201
- Email: Relma-celMedical@jwtherapeutics.com
Study Locations
-
-
-
Shanghai, China
- Recruiting
- Relma-cel Medical
-
Contact:
- medical Relma-cel
-
Principal Investigator:
- chunli Mei
-
Principal Investigator:
- Heng Mei
-
Principal Investigator:
- liangjing Lv
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Sign an informed consent form (ICF) voluntarily.
- At the time of signing the ICF, you must be between 18 and 70 years old (inclusive), male or female.
- A diagnosis of SLE according to the 1997 revised criteria of the American College of Rheumatology (ACR).
- The history of SLE prior to screening was at least 6 months, and the disease remained active at least 2 months after the use of a stable standard SLE regimen prior to screening.
Standard treatment regimen refers to the steady use of any of the following (alone or in combination) : corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and other immunosuppressants or immunomodulators including azathioprine, Mycophenolate Mofetil, cyclophosphamide, methotrexate, leflunomide, tacrolimus, and cyclosporine.
Oral corticosteroids must meet the following requirements:
- Prednisone (or equivalent) ≥7.5 mg/ day, and ≤30 mg/ day.
- There is no minimum daily dose requirement for corticosteroids when used in combination with immunosuppressants.
- At least 8 weeks of treatment prior to screening, and the dose must be kept stable for > 2 weeks.
5. Screening is positive for antinuclear antibodies, and/or anti-DS-DNA antibodies, and/or anti-Smith antibodies.
6. SELENA-SLEDAI score ≥8 during the screening period. Score ≥6 for SELENA-SLEDAI clinical symptoms (except for low complement and/or anti-DS-DNA antibodies) if low complement and/or anti-DS-DNA antibody score is present.
Exclusion Criteria:
- Severe lupus nephritis (defined as proteinuria > 6 g/24h or serum creatinine > 2.5 mg/dL or 221 μmol/L), treatment with active nephritis with Prohibited drugs, hemodialysis, or prednisone ≥100 within 8 weeks prior to screening mg/d or equivalent glucocorticoid therapy ≥14 days.
- Prior to screening, other lupus crises, such as active central nervous system lupus, severe hemolytic anemia, severe thrombocytopenic purpura, severe agranulocytosis, severe myocardial damage, severe lupus pneumonia or pulmonary hemorrhage, severe lupus hepatitis, and severe vasculitis.
- Clinically significant central nervous system diseases or pathological changes not caused by lupus prior to screening, including but not limited to: cerebrovascular accident, aneurysm, epilepsy, convulsions/convulsions, aphasia, stroke, severe brain injury, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, or psychosis.
- Combined with other autoimmune diseases, systematic treatment is needed.
- History of major organ transplantation (e.g., heart, lung, kidney, liver) or hematopoietic stem cell/bone marrow transplantation.
- IgA deficiency was present during screening (serum IgA level < 10 mg/dL)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Relma-cel be administrated in four dose level
|
CD19-targeted Chimeric AntigenReceptor (CAR) T Cells; Relma-cel be administrated at four dose level:25×106 CAR+ T cells、50×106 CAR+ T cells、100×106 CAR+ T cells/150×106 CAR+ T cells
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
DLT rate
Time Frame: 3 months
|
The incidence of dose-limiting toxicity
|
3 months
|
determine RP2D
Time Frame: 3 months
|
To determine RP2D(Phase 2 recommended dose)
|
3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Autoantibody detection
Time Frame: 3 months
|
Autoantibody detection up to 3 months after CD19 cCAR T cells infusion
|
3 months
|
SELENA-SLEDAI (Safety of Estrogens in Systemic Lupus Erythematosus National Assessment) score; 0 to 4 is basically no disease activity; 5 to 9 is light activity; 10 to 14 is moderate activity;≥15 is considered heavy activity.
Time Frame: 3 months
|
SELENA-SLEDAI score taken up to 3 months after CD19 cCAR T cells infusion
|
3 months
|
BILAG -2004(updated version of british isles lupus assessment group ) level;The BILAG 2004 index categorizes disease activity into 5 different levels from A-E.Grade A represents very active disease.
Time Frame: 3 months
|
BILAG-2004 level taken up to 3 months after CD19 cCAR T cells infusion
|
3 months
|
PGA (physician global assessment) score,The PGA scale ranges from "no disease activity" (0) to the "most severe disease activity" (3).the score is between 0 to 3.
Time Frame: 3 months
|
PGA score taken up to 3 months after CD19 cCAR T cells infusion
|
3 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: yu Hu, Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology
- Principal Investigator: heng Mei, Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology
- Principal Investigator: liangjing Lv, Renji Hospital Shanghai Jiaotong University School of Medical
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- JWCAR029012
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Systemic Lupus Erythematosus
-
SanofiCompletedCutaneous Lupus Erythematosus-Systemic Lupus ErythematosusJapan
-
Kyowa Kirin Co., Ltd.RecruitingHealthy Volunteers | Systemic Lupus Erythematosus (SLE) | Cutaneous Lupus Erythematosus (CLE)Japan
-
Second Xiangya Hospital of Central South UniversityNational Natural Science Foundation of China; Hunan Provincial Natural Science... and other collaboratorsActive, not recruitingCutaneous Lupus Erythematosus | Systemic Lupus Erythematosus RashChina
-
University Hospital, BrestRecruitingSystemic Lupus Erythematosus (SLE)France
-
Beijing InnoCare Pharma Tech Co., Ltd.RecruitingSystemic Lupus Erythematosus, SLEChina
-
TJ Biopharma Co., Ltd.TerminatedSystemic Lupus Erythematosus (SLE)China
-
AstraZenecaActive, not recruitingActive Systemic Lupus ErythematosusThailand, Korea, Republic of, Philippines, China, Taiwan, Hong Kong
-
Novartis PharmaceuticalsActive, not recruitingSystemic Lupus Erythematosus (SLE)Hungary, Spain, Germany, Israel, Thailand, France, Russian Federation, China, Japan, Taiwan, Korea, Republic of, Poland, Australia, Argentina, Czechia
-
AstraZenecaPRA Health SciencesCompletedActive Systemic Lupus ErythematosusUnited States, France, Germany, Spain, Belgium, Russian Federation, Japan, Korea, Republic of, Argentina, Bulgaria, South Africa, Mexico, Canada, Brazil, Lithuania
-
Novartis PharmaceuticalsNot yet recruitingSystemic Lupus Erythematosus, SLE
Clinical Trials on Relma-cel
-
Ruijin HospitalNot yet recruitingB-NHL, Extranodal, TP53 Alterations, Bulky Mass
-
Shanghai Ming Ju Biotechnology Co., Ltd.Not yet recruitingSystemic Lupus Erythematosus
-
Chinese PLA General HospitalRecruiting
-
TruDiagnosticSRWRecruiting
-
Weill Medical College of Cornell UniversityAngiocrine BioscienceRecruiting
-
Kamau TherapeuticsRecruitingSickle Cell DiseaseUnited States
-
University Medical Center GroningenStichting Hemato-Oncologie voor Volwassenen NederlandRecruitingNHL | DLBCL - Diffuse Large B Cell LymphomaNetherlands
-
Vertex Pharmaceuticals IncorporatedCRISPR TherapeuticsEnrolling by invitationHematologic Diseases | Genetic Diseases, Inborn | Sickle Cell Disease | Hemoglobinopathies | Sickle Cell Anemia | Thalassemia | Beta-ThalassemiaUnited States, Canada, Italy, United Kingdom, Germany
-
CelgeneCompletedLymphoma, Non-HodgkinItaly, Switzerland, Austria, Belgium, France, Germany, Japan, Netherlands, Spain, United Kingdom, Finland